GC launched the Mogam Institute for Biomedical Research, its nonprofit research wing, in 1984 with the proceeds it earned from Hepavax, the company’s hepatitis-B vaccine (the third successful one in the country).
The institute is tasked with promoting advances in biomedical technology, reinvesting its profits in fostering a stable and conducive environment for research. It is also the first-ever nonprofit research corporation established with the Ministry of Science and Technology (currently the Ministry of Science and ICT) in Korea.
We are conducting research to develop new drugs using artificial intelligence.